Isis Spinoff Altair Therapeutics Shut Down, After Mid-Stage Asthma Study Fails – Xconomy

Isis Spinoff Altair Therapeutics Shut Down, After Mid-Stage Asthma Study Fails
Xconomy
has shut down operations after the startup's only drug candidate failed in a mid-stage clinical trial against asthma, Xconomy has learned.

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.